Inactive Instrument

Analyst Reco. Surface Oncology, Inc.

Equities

Wedbush Downgrades Surface Oncology to Neutral From Outperform, Adjusts Price Target to $1.15 From $3	20/06/23	MT
Baird Downgrades Surface Oncology to Neutral From Outperform, Cuts Price Target to $1 From $6	20/06/23	MT
HC Wainwright Downgrades Surface Oncology to Neutral From Buy, Price Target is $5	20/06/23	MT
HC Wainwright Adjusts Surface Oncology's Price Target to $6 From $8.50, Keeps Buy Rating	03/11/22	MT
Wedbush Cuts Price Target on Surface Oncology to $3 From $12, Citing New Clinical Data, Updated Pipeline Focus; Outperform Rating Kept	03/11/22	MT
HC Wainwright Adjusts Price Target on Surface Oncology to $8.50 From $10, Reiterates Buy Rating	08/08/22	MT
Wedbush Cuts Price Target on Surface Oncology to $12 From $14, Citing 'Future Financing Assumptions,' Keeps Outperform Rating	12/05/22	MT
SURFACE ONCOLOGY : Wedbush Adjusts Price Target for Surface Oncology to $14 From $18, Maintains Outperform Rating	05/08/21	MT
SURFACE ONCOLOGY : BTIG Initiates Surface Oncology at Buy Rating With $17 Price Target	18/05/21	MT
SURFACE ONCOLOGY : Wedbush Raises Price Target for Surface Oncology to $18 From $15, Maintains Outperform Rating	17/12/20	MT
SURFACE ONCOLOGY : Wedbush Adjusts Price Target on Surface Oncology to $15 From $12, Keeps Outperform Rating	16/11/20	MT

No results for this search